Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Key Inclusion Criteria:

• Males or females who may benefit from filgotinib as judged by the investigator ANDwho completed a Gilead sponsored filgotinib parent study for RA as outlined below:

• Have completed GS-US-417-0301, GS-US-417-0302 or GS-US-417-0303 on study drug

• OR

• Have completed GS-US-417-0302 on standard of care therapy due to RAnon-responder status

• Females of childbearing potential must have a negative pregnancy test prior to firstdose of study drug in the long term extension (LTE)

• Females of childbearing potential who engage in heterosexual intercourse must agreeto protocol-approved methods of contraception

Key Exclusion Criteria:

• Diagnosis of an autoimmune or inflammatory joint disease other than RA, which wouldput the participant at risk by participating in the study or would interfere withstudy assessments/data interpretation, per judgment of the investigator

• Known hypersensitivity to the study drug or its excipients

• Any medical condition which would put the participant at risk by participating inthe study or would interfere with study assessments/data interpretation, perjudgment of the investigator

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.